Literature DB >> 34110889

Sleep disturbance as a therapeutic target to improve opioid use disorder treatment.

Andrew S Huhn1, Patrick H Finan1.   

Abstract

Sleep health is an important factor across several physical and mental health disorders, and a growing scientific consensus has identified sleep as a critical component of opioid use disorder (OUD), both in the active disease state and during OUD recovery. The goal of this narrative review is to collate the literature on sleep, opioid use, and OUD as a means of identifying therapeutic targets to improve OUD treatment outcomes. Sleep disturbance is common and often severe in persons with OUD, especially during opioid withdrawal, but also in persons on opioid maintenance therapies. There is ample evidence that sleep disturbances including reduced total sleep time, disrupted sleep continuity, and poor sleep quality often accompany negative OUD treatment outcomes. Sleep disturbances are bidirectionally associated with several other factors related to negative treatment outcomes, including chronic stress, stress reactivity, low positive affect, high negative affect, chronic pain, and drug craving. This constellation of outcome variables represents a more comprehensive appraisal of the quality of life and quality of recovery than is typically assessed in OUD clinical trials. To date, there are very few clinical trials or experimental studies aimed at improving sleep health in OUD patients, either as a means of improving stress, affect, and craving outcomes, or as a potential mechanistic target to reduce opioid withdrawal and drug use behaviors. As such, the direct impact of sleep improvement in OUD patients is largely unknown, yet mechanistic and clinical research suggests that therapeutic interventions that target sleep are a promising avenue to improve OUD treatment. (PsycInfo Database Record (c) 2021 APA, all rights reserved).

Entities:  

Year:  2021        PMID: 34110889      PMCID: PMC8660927          DOI: 10.1037/pha0000477

Source DB:  PubMed          Journal:  Exp Clin Psychopharmacol        ISSN: 1064-1297            Impact factor:   3.157


  167 in total

Review 1.  GABA mechanisms and sleep.

Authors:  Claude Gottesmann
Journal:  Neuroscience       Date:  2002       Impact factor: 3.590

Review 2.  Hypothalamic regulation of sleep and circadian rhythms.

Authors:  Clifford B Saper; Thomas E Scammell; Jun Lu
Journal:  Nature       Date:  2005-10-27       Impact factor: 49.962

3.  Central orexin-A activates hypothalamic-pituitary-adrenal axis and stimulates hypothalamic corticotropin releasing factor and arginine vasopressin neurones in conscious rats.

Authors:  K A Al-Barazanji; S Wilson; J Baker; D S Jessop; M S Harbuz
Journal:  J Neuroendocrinol       Date:  2001-05       Impact factor: 3.627

4.  Effects of chronic treatment with methadone and naltrexone on sleep in addicts.

Authors:  J Staedt; F Wassmuth; G Stoppe; G Hajak; A Rodenbeck; W Poser; E Rüther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

5.  Sleep and GABA levels in the oral part of rat pontine reticular formation are decreased by local and systemic administration of morphine.

Authors:  C J Watson; R Lydic; H A Baghdoyan
Journal:  Neuroscience       Date:  2006-10-19       Impact factor: 3.590

6.  The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress.

Authors:  Rachel Y Chong; Lynn Oswald; Xiaoju Yang; Magdalena Uhart; Ping-I Lin; Gary S Wand
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

7.  A role for lateral hypothalamic orexin neurons in reward seeking.

Authors:  Glenda C Harris; Mathieu Wimmer; Gary Aston-Jones
Journal:  Nature       Date:  2005-08-14       Impact factor: 49.962

8.  Psychobiological responses to drug cues before and after methadone intake in heroin-dependent patients: a pilot study.

Authors:  Marc Walter; Gerhard A Wiesbeck; Nicole Bloch; Sacha Aeschbach; Hans M Olbrich; Erich Seifritz; Kenneth M Dürsteler-MacFarland
Journal:  Eur Neuropsychopharmacol       Date:  2008-03-04       Impact factor: 4.600

Review 9.  Opioids and sleep.

Authors:  Nicholas J Cutrufello; Vlad D Ianus; James A Rowley
Journal:  Curr Opin Pulm Med       Date:  2020-11       Impact factor: 3.155

10.  Daily sleep quality affects drug craving, partially through indirect associations with positive affect, in patients in treatment for nonmedical use of prescription drugs.

Authors:  David M Lydon-Staley; H Harrington Cleveland; Andrew S Huhn; Michael J Cleveland; Jonathan Harris; Dean Stankoski; Erin Deneke; Roger E Meyer; Scott C Bunce
Journal:  Addict Behav       Date:  2016-08-15       Impact factor: 3.913

View more
  3 in total

1.  Clinical correlates of drug-related dreams in opioid use disorder.

Authors:  Jennifer D Ellis; Jami L Mayo; Patrick H Finan; Charlene E Gamaldo; Andrew S Huhn
Journal:  Am J Addict       Date:  2021-08-29

2.  Endogenous opioid signaling in the retina modulates sleep/wake activity in mice.

Authors:  Casey-Tyler Berezin; Nikolas Bergum; Kes A Luchini; Sierra Curdts; Christian Korkis; Jozsef Vigh
Journal:  Neurobiol Sleep Circadian Rhythms       Date:  2022-06-26

Review 3.  A retinal contribution to opioid-induced sleep disorders?

Authors:  Nikolas Bergum; Casey-Tyler Berezin; Jozsef Vigh
Journal:  Front Neurosci       Date:  2022-08-05       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.